chevron_leftBack
As of 13 June 2026, Perseus Proteomics Inc. has a market cap of $20.49M USD, ranking #36907 globally and #3550 in Japan.
It ranks #3311 in the Healthcare sector, and #1107 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$20.49MUSD
3.28B JPY
Enterprise Value
$12.75MUSD
2.05B JPY
Revenue (TTM)
$877.11KUSD
140.41M JPY
Net Income (TTM)
-$4.74MUSD
-758.12M JPY
PS Ratio
23.4
PB Ratio
3.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Takuya Yokokawa
open_in_new
Employees
32
Founded
2001
Website
ppmx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.8% | -3.2% | -12% | -9.3% | -25% | -48% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4882
株式会社 ペルセウスプロテオミクス
ISIN: JP3836800007
Shares Out.:
Shares Outstanding:
17.0M1
Shares Float:
16.076M2
|
214 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Perseus Proteomics Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TSE: 4519
|
$81.63B
398K%
13.07T JPY
|
28.9
|
|
TSE: 4502
|
$52.2B
255K%
8.36T JPY
|
75.1
|
|
TSE: 4578
|
$36.83B
180K%
5.9T JPY
|
15.7
|
|
TSE: 4568
|
$30.36B
148K%
4.86T JPY
|
16.2
|
|
TSE: 4503
|
$25.81B
126K%
4.13T JPY
|
14.2
|
|
TSE: 4507
|
$16.9B
82K%
2.71T JPY
|
13.9
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
4M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
3M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
2M%
|
97.4
|
|
SIX: RO
|
$321.52B
2M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
chevron_leftBack